Andere Sprachen Dyne Therapeutics, Inc.

Aktien

A2QB6B

US26818M1080

DYN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 10.06.2024			% 5 Tage	% 1. Jan.
31,5 ^USD	+1,81 %		+0,29 %	+136,84 %

23.05.	Dyne Therapeutics Insider verkaufte Aktien im Wert von $1.002.751, laut einer aktuellen SEC Einreichung	MT
22.05.	Dyne Therapeutics gibt Preis für 325,5 Millionen Dollar Stammaktien bekannt	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Dyne Therapeutics : Company Overview May 2024	31.05.
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference	30.05.
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares	28.05.
Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing	23.05.
Dyne Therapeutics Prices $325.5 Million Common Stock Offering	22.05.
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock	22.05.
Dyne Therapeutics Launches $300 Million Share Offering	20.05.
Dyne Therapeutics Announces Proposed Public Offering of Common Stock	20.05.
Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles	20.05.
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	20.05.
Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles	20.05.
Dyne Therapeutics : ACHIEVE & DELIVER Clinical Update Presentation	20.05.
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints	20.05.
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints	20.05.
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET	19.05.
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET	19.05.
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights	02.05.
Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer	27.03.
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium	27.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Dyne Therapeutics, Inc.

Aktien

A2QB6B

US26818M1080

DYN

Andere Sprachen

Filter